MAPK3 and lung cancer: Previous studies have shown that ERCC1 induction by cisplatin was dependent on the MAPK pathway [31] and that blocking ERK1/2 activation decreased cisplatin-induced ERCC1 protein levels in lung cancer and melanoma cell lines [38].